PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?

Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting

(2017) Teresa Gamucci et al.   JOURNAL OF CELLULAR PHYSIOLOGY

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)

(2017) Nobumoto Tomioka et al.   Breast Cancer

The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer

(2017) Hitomi Mori et al.   Oncotarget

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome

(2016) Rhiannon K Beckers et al.   HISTOPATHOLOGY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study

(2016) Zhiying Shao et al.   ONCOLOGY RESEARCH

Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients

(2016) Marius Ilie et al.   VIRCHOWS ARCHIV

Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer

(2015) G. Pruneri et al.   ANNALS OF ONCOLOGY

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer

(2013) A N Seo et al.   BRITISH JOURNAL OF CANCER

The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy

(2013) François Ghiringhelli et al.   Expert Review of Clinical Immunology

Triple-negative breast cancer: epidemiological considerations and recommendations

(2012) P. Boyle   ANNALS OF ONCOLOGY

Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer

(2012) Rin Yamaguchi et al.   HUMAN PATHOLOGY

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

(2011) Makiko Ono et al.   BREAST CANCER RESEARCH AND TREATMENT

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

(2008) Priya Rastogi et al.   JOURNAL OF CLINICAL ONCOLOGY

Interaction of human PD-L1 and B7-1

(2008) Manish J. Butte et al.   MOLECULAR IMMUNOLOGY